MedTrace Logo

Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome

NCT01670357 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2014-10-01

No results posted yet for this study

Summary

This study is to determine the efficacy and safety of 3% or 5% DA-6034 eye drops compared with placebo in dry eye syndrome.

Conditions

  • Dry Eye Syndrome

Interventions

DRUG

DA-6034 3%

Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks

DRUG

DA-6034 5%

Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks

DRUG

DA-6034 Placebo

Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • ManSoo Kim, M.D. · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01670357 on ClinicalTrials.gov